# Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)

> **NCT00864474** · — · COMPLETED · sponsor: **ViiV Healthcare** · enrollment: 68 (actual)

## Conditions studied

- CCR5-tropic HIV-1 Infection

## Interventions

- **DRUG:** CELSENTRI® Tablets

## Key facts

- **NCT ID:** NCT00864474
- **Lead sponsor:** ViiV Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03-31
- **Primary completion:** 2018-12-24
- **Final completion:** 2018-12-24
- **Target enrollment:** 68 (ACTUAL)
- **Last updated:** 2020-01-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00864474

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00864474, "Safety And Efficacy Of Maraviroc In Patients For HIV Patients (Regulatory Post Marketing Commitment Plan)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00864474. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*